Skip to main content
. Author manuscript; available in PMC: 2021 Aug 10.
Published in final edited form as: Am J Nephrol. 2020 Aug 10;51(9):715–725. doi: 10.1159/000509451

Fig. 3. Pre-end-stage renal disease (ESRD) opiate, gabapentin/pregabalin, other non-opiate analgesic, and no analgesic use and post-ESRD mortality risk across clinically relevant subgroups in the one-year prelude cohort (ref: no analgesic use).

Fig. 3.

Analyses adjusted for expanded case-mix covariates. Abbrev.: DM, diabetes; HD, hemodialysis; PD, peritoneal dialysis; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; CVD, cerebrovascular disease; CAD, coronary artery disease.